GNI Group Ltd.

GNI Group Ltd. is a pharmaceutical and biomaterials company operating in Japan, China, and the United States. It has two segments: Pharmaceutical Business and Medical Equipment Business. Its products include ETUARY for idiopathic pulmonary fibrosis, H-GENIN Crush-Mix for bone defects, AltiPly for acute and chronic wounds, and orthobiologics products. The company is also developing ETUARY in Phase III trials for pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; F351 in Phase III for chronic hepatitis B liver fibrosis; ETUARY in Phase II for radiation-induced lung injury with or without immune-related pneumonitis; F573 in Phase II for acute liver failure and acute-on-chronic liver failure; F351 in Phase I for MASH-advanced liver fibrosis; F230 in Phase I for pulmonary arterial hypertension; CG001419 in Phase Ia for acute and chronic pain and for solid tumors; and CG009301 in Phase Ia for leukemia and MYC+ cancers. Incorporated in 2001, it is headquartered in Chuo, Japan.